Bimekizumab vs Upadacitinib

## Bimekizumab vs Upadacitinib: Overview

This comparison examines the pharmacological differences between **Bimekizumab** and **Upadacitinib**.

## Mechanism of Action

**Upadacitinib**: Selective JAK1 inhibitor reducing signaling from cytokines implicated in autoimmune diseases.

## Pharmacokinetics

**Half-life**: Bimekizumab — N/A; Upadacitinib — 9-14 hours.

## Chemical Properties

**Molecular Formula**: Bimekizumab — N/A; Upadacitinib — C17H19F3N6O.

**Molecular Weight**: Bimekizumab — N/A; Upadacitinib — 380.3700 g/mol.

**Type**: Bimekizumab — Antibody; Upadacitinib — Small molecule.